Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Spektrum der Augenheilkunde
Erschienen in:

01.06.2013 | bericht

Leitbild Diagnose und Therapie retinaler Venenverschlüsse

verfasst von: Martin Weger, Univ. Doz. Dr. Stefan Egger, für die Netzhautkommission

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Auszug

Retinale Venenverschlüsse stellen die zweithäufigste Netzhautgefäßerkrankung nach der diabetischen Retinopathie dar. Je nach Lokalisation des Verschlusses unterscheidet man einen Zentral-, Hemiretinal- und Astvenenverschluss. Diese unterscheiden sich nicht nur in der Lokalisation des Verschlusses, sondern auch in der Visusprognose, Art und Prävalenz der Risikofaktoren und teils in den zur Verfügung stehenden Therapieoptionen. …
Vorheriger Artikel Empfehlungen der NH Kommission der ÖOG zur Durchführung einer IVOM (intravitreale operative Medikamentenapplikation) Oktober 2012
Nächster Artikel Nachruf auf Doktor Stergios Nichorlis

Literatur
1.
Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia and Australia. Ophthalmology. 2010;117:313–9.PubMedCrossRef
2.
Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol. 2001;131:61–77.PubMedCrossRef
3.
Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994;117:429–41.PubMed
4.
Deramo VA, Cox TA, Syed AB, Lee PP, Fekrat S. Vision-related quality of life in people with central retinal vein occlusion using the 25-item national eye institute visual function questionnaire. Arch Ophthalmol. 2003;121:1297–302.PubMedCrossRef
5.
Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S. Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item national eye institute visual function questionnaire. Br J Ophthalmol. 2010;94:319–23.PubMedCrossRef
6.
Cugati S, Wang JJ, Knudtson MD, et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology. 2007;114:520–4.PubMedCrossRef
7.
Werther W, Chu L, Holekamp N, Do DV, Rubio RG. Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion. Arch Ophthalmol. 2011;129:326–31.PubMedCrossRef
8.
Ho JD, Liou SW, Lin HC. Retinal vein occlusion and the risk of stroke development: a five-year follow-up study. Am J Ophthalmol. 2009;137:283–90.CrossRef
9.
O’Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 2008;126:692–9.PubMedCrossRef
10.
Stojakovic T, Scharnagl H, März W, Winkelmann BR, Boehm BO, Schmut O. Low density lipoprotein triglycerides and lipoprotein(a) are risk factors for retinal vascular occlusion. Clin Chim Acta. 2007;382:77–81.PubMedCrossRef
11.
The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol. 1996;114:545–54.CrossRef
12.
The Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol. 1993;116:286–96.
13.
Hayreh SS, Zimmerman MB, Beri M, Podhajsky P. Intraocular pressure abnormalities associated with central and hemiretinal vein occlusion. Ophthalmology. 2004;111:133–41.PubMedCrossRef
14.
Kimmel AS, McCarthy MJ, Blodi CF, Folk JC. Branch retinal vein occlusion in sarcoidosis. Am J Ophthalmol. 1989;107:561–2.PubMed
15.
Lobes LA Jr, Folk JC. Syphilitic phlebitis simulating branch vein occlusion. Ann Ophthalmol. 1981;13:825–7.PubMed
16.
The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115:486–91.CrossRef
17.
Consensus Statement. Retinaler Venenverschluss (RVV). Diagnostik und Therapie. Österreichische Ärztezeitung 2012; Supplementum Februar:1–11.
18.
The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271–82.
19.
Gutman FA, Zegarra H. The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol. 1974;78:OP178–92.
20.
Michels RG, Gass JD. The natural course of retinal branch vein obstruction. Trans Am Acad Ophthalmol Otolaryngol. 1974;87:OP166–77.
21.
Hayreh SS, Zimmerman MB. Hemicentral retinal vein occlusion: natural history of visual outcome. Retina. 2012;32:68–76.PubMedCrossRef
22.
Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009;50:1025–32.PubMedCrossRef
23.
Lim JW. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion. Ophthalmologica. 2011;225:150–4.PubMedCrossRef
24.
Koss MJ, Pfister M, Rothweiler F, et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol. 2012;90(2):e98–e103. doi: 10.1111/j.1755-3768.2011.02292.x.PubMedCrossRef
25.
Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102–12.PubMedCrossRef
26.
Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118:1594–602.PubMedCrossRef
27.
Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124–33.PubMedCrossRef
28.
Campochiaro PA, Brown DA, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118:2041–9.PubMedCrossRef
29.
Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802–9.PubMedCrossRef
30.
Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009;93:452–6.PubMedCrossRef
31.
Wu L, Arevalo JF, Berrocal MH, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina. 2009;29:1396–403.PubMedCrossRef
32.
Wu L, Arevalo JF, Berrocal MH, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina. 2010;30:1002–11.PubMedCrossRef
33.
Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008;92:351–5.PubMedCrossRef
34.
Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007;27:1004–12.PubMedCrossRef
35.
Wroblewski JJ, Wells JA 3rd, Adamis AP, et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol. 2009;127:374–80.PubMedCrossRef
36.
Wroblewski JJ, Wells JA 3rd, Gonzales CR. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. Am J Ophthalmol. 2010;149:147–54.PubMedCrossRef
37.
Clark W. VEGF Trap-Eye for Retinal Vein Occlusion: COPERNICUS and GALLILEO, American Academy of Ophthalmology 2011.
38.
Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119:1024–32.PubMedCrossRef
39.
Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4:e8158.PubMedCrossRef
40.
Nehme A, Edelman J. Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1 beta induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Invest Ophthalmol Vis Sci. 2008;49:2030–8.PubMedCrossRef
41.
McAllister IL, Vijaysekaran S, Chen SD, Yu DY. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol. 2009;147:838–46.PubMedCrossRef
42.
Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115–28.PubMedCrossRef
43.
Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127:1101–14.PubMedCrossRef
44.
Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve month study results. Ophthalmology. 2011;118:2453–60.PubMedCrossRef
45.
The Central Vein Occlusion Study Group M report. Evaluation of grid pattern photocoagulation for macular edema in central retinal vein occlusion. Ophthalmology. 1995;102(10):1425–33.
46.
The Central Vein Occlusion Study Group N report. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. Ophthalmology. 1995;102:1434–44.
47.
Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie des Makulaödems beim retinalen Venenverschluss. 2010. http://​www.​dog.​org.​ Zugriffsdaten: 29.11.2011
Metadaten
Titel
Leitbild Diagnose und Therapie retinaler Venenverschlüsse
verfasst von
Martin Weger
Univ. Doz. Dr. Stefan Egger
für die Netzhautkommission
Publikationsdatum
01.06.2013
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 3/2013
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-012-0128-3

Weitere Artikel der Ausgabe 3/2013

Natural closure mechanisms of idiopathic macular holes

  • case report

KONGRESSKALENDER

  • kongresskalender

Wird die Ophthalmologie eine „Komfortmedizin“?

  • editorial

Nachruf auf Doktor Stergios Nichorlis


  • nachruf

Weitsichtigkeit als Risikofaktor für Patienten mit nicht-arteritischeranteriorer ischämischer Optikusneuropathie

  • originalarbeit

How reliable is laser ablation depth readout when planning corneal refractive surgery?

  • original article